Chest
Original ResearchCOPDHelium-Hyperoxia: A Novel Intervention To Improve the Benefits of Pulmonary Rehabilitation for Patients With COPD
Section snippets
Patients
Patients with stable COPD (post bronchodilator FEV1/FVC < 0.7, FEV1<80% predicted) who were exacerbation-free for > 1 month prior to study entry were recruited from the Caritas Centre for Lung Health, Edmonton, Canada. Patients were excluded if they had cardiovascular and/or musculoskeletal contraindications that limited exercise participation and if they had exertional hypoxemia indicated by an oxyhemoglobin saturation < 85% during any of the preliminary exercise trials breathing air. All
Results
Participant flow through the study is presented in detail in Figure 1. Patients were enrolled between March 2005 and November 2006. Of the 441 patients who were referred to rehabilitation, the main reasons for excluding patients were: patients had diseases other than COPD (121/441), patients were on supplemental O2 (73/441), patients declined rehabilitation (71/441), patients had cardiovascular disease that limited their ability to perform exercise (32/441), patients had known exertional
Discussion
This is the first study to investigate the effect of breathing HH during rehabilitation in patients without hypoxemia and with COPD. This proof-of-concept study supports the hypothesis that HH can augment the known benefits of a comprehensive pulmonary rehabilitation program, as CLT and total SGRQ score improved more following rehabilitation with HH than with the standard practice of rehabilitation breathing air.
The greater increase in CLT in the HH group supports our hypothesis that if a
Acknowledgment
The authors thank Monica Pratley, Sharon Martin, Tina Jourdain, Lindsay Simmonds, Rashida Hamir, and Barb Gendron for their support with all aspects of the study.
References (32)
- et al.
The effects of helium-hyperoxia on 6-min walking distance in COPD: a randomized, controlled trial
Chest
(2007) - et al.
Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD
Chest
(2005) - et al.
Endurance training in patients with chronic obstructive pulmonary disease: a comparison of high versus moderate intensity
Arch Phys Med Rehabil
(2000) - et al.
Effects of training with heliox and noninvasive positive pressure ventilation on exercise ability in patients with severe COPD
Chest
(2002) - et al.
Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial
Lancet
(2000) - et al.
Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease
Am J Respir Crit Care Med
(2001) - et al.
Helium-hyperoxia, exercise, and respiratory mechanics in chronic obstructive pulmonary disease
Am J Respir Crit Care Med
(2006) - et al.
Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease
Am J Respir Crit Care Med
(2001) - et al.
Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients
J Appl Physiol
(2004) - et al.
The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trial
Am J Respir Crit Care Med
(2006)
Pulmonary rehabilitation: Joint ACCP/AACVPR evidence-based clinical practice guidelines
Chest
A controlled trial of the effects of leg training on breathing pattern and dynamic hyperinflation in severe COPD
Lung
Training improves muscle oxidative capacity and oxygenation recovery kinetics in patients with chronic obstructive pulmonary disease
Eur J Appl Physiol
Comparison of two training programmes in chronic airway limitation patients: standardized versus individualized protocols
Eur Respir J
Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Noninvasive ventilation with helium-oxygen in acute exacerbations of chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Cited by (0)
Funding for this study was provided by the Medical Services Incorporated Foundation and the Caritas Health Group.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).
- 1
Dr. Ford has received honoraria and travel expenses for speaking at scientific meetings and continuing medical education courses from GlaxoSmithKline for $16,500 in 2005, $7,500 in 2006, and $14,000 in 2007. He has also received research funding from GlaxoSmithKline as a principal investigator for $135,000 between 2001–2005, Altana Pharma as a coinvestigator for $80,000 from 2004–2006, and $92,266 from GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim, Canada, Limited as a coinvestigator from 2004 to 2006. Dr. Ford has also received honoraria and travel expenses for participating on medical advisory boards for various pharmaceutical companies (GSK, AstraZeneca, and Boehringer Ingelheim, Canada, Limited, Altana Pharma, Pfizer Canada, and Abbott Canada). The other authors have no conflicts of interest to disclose.